Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in Active Melanoma Brain Metastases
NCT05704647Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2023
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab, nivolumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2023; status: recruiting.
02
Drugs
relatlimabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05704647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704647.